TY - JOUR
T1 - Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia
T2 - Innocent or Guilty?
AU - Dekker, Linde
AU - Sanders, Evy
AU - Lindemans, Caroline A.
AU - de Koning, Coco
AU - Nierkens, Stefan
N1 - Copyright © 2022 Dekker, Sanders, Lindemans, de Koning and Nierkens.
PY - 2022/6/20
Y1 - 2022/6/20
N2 - The outcome of allogeneic hematopoietic cell transplantation (allo-HCT) largely depends on the development and management of graft-versus-host disease (GvHD), infections, and the occurrence of relapse of malignancies. Recent studies showed a lower incidence of chronic GvHD and severe acute GvHD in patients receiving naive T cell depleted grafts compared to patients receiving complete T cell depleted grafts. On the other hand, the incidence of acute GvHD in patients receiving cord blood grafts containing only naive T cells is rather low, while potent graft-versus-leukemia (GvL) responses have been observed. These data suggest the significance of naive T cells as both drivers and regulators of allogeneic reactions. The naive T cell pool was previously thought to be a quiescent, homogenous pool of antigen-inexperienced cells. However, recent studies showed important differences in phenotype, differentiation status, location, and function within the naive T cell population. Therefore, the adequate recovery of these seemingly innocent T cells might be relevant in the imminent allogeneic reactions after allo-HCT. Here, an extensive review on naive T cells and their contribution to the development of GvHD and GvL responses after allo-HCT is provided. In addition, strategies specifically directed to stimulate adequate reconstitution of naive T cells while reducing the risk of GvHD are discussed. A better understanding of the relation between naive T cells and alloreactivity after allo-HCT could provide opportunities to improve GvHD prevention, while maintaining GvL effects to lower relapse risk.
AB - The outcome of allogeneic hematopoietic cell transplantation (allo-HCT) largely depends on the development and management of graft-versus-host disease (GvHD), infections, and the occurrence of relapse of malignancies. Recent studies showed a lower incidence of chronic GvHD and severe acute GvHD in patients receiving naive T cell depleted grafts compared to patients receiving complete T cell depleted grafts. On the other hand, the incidence of acute GvHD in patients receiving cord blood grafts containing only naive T cells is rather low, while potent graft-versus-leukemia (GvL) responses have been observed. These data suggest the significance of naive T cells as both drivers and regulators of allogeneic reactions. The naive T cell pool was previously thought to be a quiescent, homogenous pool of antigen-inexperienced cells. However, recent studies showed important differences in phenotype, differentiation status, location, and function within the naive T cell population. Therefore, the adequate recovery of these seemingly innocent T cells might be relevant in the imminent allogeneic reactions after allo-HCT. Here, an extensive review on naive T cells and their contribution to the development of GvHD and GvL responses after allo-HCT is provided. In addition, strategies specifically directed to stimulate adequate reconstitution of naive T cells while reducing the risk of GvHD are discussed. A better understanding of the relation between naive T cells and alloreactivity after allo-HCT could provide opportunities to improve GvHD prevention, while maintaining GvL effects to lower relapse risk.
KW - allogeneic hematopoietic cell transplantation
KW - alloreactivity
KW - graft versus host disease
KW - graft versus leukemia
KW - naive T cells
KW - Recurrence
KW - Humans
KW - Leukemia/complications
KW - Graft vs Host Disease/prevention & control
KW - T-Lymphocytes/pathology
KW - Transplantation, Homologous/adverse effects
KW - allogeneic hematopoietic cell transplantation
KW - alloreactivity
KW - graft versus host disease
KW - graft versus leukemia
KW - naive T cells
UR - http://www.scopus.com/inward/record.url?scp=85133636550&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/254b9c1e-a0a5-3110-a729-bdad65c27e4c/
U2 - 10.3389/fimmu.2022.893545
DO - 10.3389/fimmu.2022.893545
M3 - Article
C2 - 35795679
AN - SCOPUS:85133636550
SN - 1664-3224
VL - 13
SP - 893545
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 893545
ER -